PolyPid (PYPD) has released an update.
PolyPid Ltd. has discussed the rising challenge of surgical site infections (SSIs) and highlighted its ongoing SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing SSIs in abdominal surgeries. The trial has currently enrolled about 250 of the planned 600 patients, with interim analysis expected after 400 patients complete a 30-day follow-up, and top-line results anticipated in early 2025. The company’s D-PLEX100 product, which releases antibiotics over 30 days, could improve patient outcomes and reduce healthcare costs associated with SSIs.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
